ADVerse outcome Network for non-mutagenic CarcinogEns

Projektinformationen

ADVaNCE

ID Finanzhilfevereinbarung: 750195

DOI 10.3030/750195

Abgeschlossenes Projekt

EK-Unterschriftsdatum 4 September 2017

Startdatum 1 Oktober 2017

Enddatum 30 September 2019

Finanziert unter

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Gesamtkosten € 187 419,60

EU-Beitrag € 187 419,60

Koordiniert durch

EDELWEISS CONNECT GMBH
Switzerland

Ziel

The field of toxicology is evolving from purely descriptive to a highly data‐rich science. To structure this large amount of data and in this way make the usage more effective for the safety assessors, the concept of adverse outcome pathways was established providing a means of understanding how chemicals induce adverse effects through their toxicity pathways and modes of action. However, there are some doubts if the one initiating event - one adverse outcome relationship enforced on AOPs by the OECD guideline is able to cover more complex adverse effects like hepatocellular carcinoma resulting from non-mutagenic chemical exposure. Therefore, the ADVaNCE project will demonstrate based on the just mentioned example that combining all existing knowledge into an adverse outcome network formed by interlinked AOPs is needed to cover all the pathways and intervention points activated in order to contribute to the development of hepatocellular carcinomas. Computational approaches will be used to extract important key events and their relationships from existing data sources and the relevant literature. These will be compared with existing AOPs and further experimental validation will be started. The computational and experimental result will finally guide the development of an integrated testing strategy completely based on in silico and in vitro data, which development and validation regarding regulatory usage will be continued after the project.

Wissenschaftliches Gebiet

• medical and health sciences › clinical medicine › oncology › liver cancer
• natural sciences › computer and information sciences › databases
• medical and health sciences › clinical medicine › hepatology
• medical and health sciences › basic medicine › toxicology
• medical and health sciences › basic medicine › pharmacology and pharmacy

Programm/Programme

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Thema/Themen

• MSCA-IF-2016 - Individual Fellowships

Aufforderung zur Vorschlagseinreichung

H2020-MSCA-IF-2016

Finanzierungsplan

MSCA-IF-EF-SE - Society and Enterprise panel

Koordinator

EDELWEISS CONNECT GMBH

• Netto-EU-Beitrag: € 187 419,60
• Adresse: HOCHBERGERSTRASSE 60C ; 4057 Basel ; Schweiz
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Region
  Schweiz/Suisse/Svizzera › Nordwestschweiz › Basel-Stadt
• Region: Schweiz/Suisse/Svizzera › Nordwestschweiz › Basel-Stadt
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: € 187 419,60